Login to Your Account

Remains 'committed to China'

GSK China closes central neuroscience research center in Shanghai

By David Ho
Staff Writer

Wednesday, August 9, 2017

HONG KONG – Glaxosmithkline plc confirmed it will be shutting down operations at its Neuroscience R&D Centre in Shanghai. The U.K.-based pharmaceutical giant will move key programs to the global R&D hub in the U.S. "following a portfolio review and prioritization," as outlined in a statement.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription